Last reviewed · How we verify
Monosialoganglioside GM1
Monosialoganglioside GM1 is a ganglioside that promotes neuronal repair and regeneration by enhancing neurite outgrowth and protecting neurons from damage.
Monosialoganglioside GM1 is a ganglioside that promotes neuronal repair and regeneration by enhancing neurite outgrowth and protecting neurons from damage. Used for Acute ischemic stroke, Peripheral nerve injury, Spinal cord injury.
At a glance
| Generic name | Monosialoganglioside GM1 |
|---|---|
| Also known as | GM1 |
| Sponsor | General Hospital of Shenyang Military Region |
| Drug class | Ganglioside |
| Target | Growth factor receptors; neuronal cell surface ganglioside receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
GM1 is a naturally occurring glycosphingolipid found in neuronal cell membranes that acts as a ligand for growth factor receptors and facilitates cell-to-cell interactions. It enhances nerve growth factor (NGF) signaling and promotes axonal regeneration, making it useful in treating peripheral nerve injuries and neurodegenerative conditions. The drug works by stabilizing neuronal membranes and promoting the survival and differentiation of nerve cells.
Approved indications
- Peripheral nerve injury and regeneration
- Acute ischemic stroke
- Spinal cord injury
- Diabetic neuropathy
Common side effects
- Injection site reactions
- Fever
- Headache
- Dizziness
Key clinical trials
- Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study (PHASE3)
- GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel (PHASE2)
- An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke (PHASE4)
- Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients (PHASE3)
- Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monosialoganglioside GM1 CI brief — competitive landscape report
- Monosialoganglioside GM1 updates RSS · CI watch RSS
- General Hospital of Shenyang Military Region portfolio CI